18 completed, 3 terminated, 2 unknown, 2 withdrawn. 26 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 26 | Completed 18, Terminated 3, Unknown 2, Withdrawn 2, Recruiting 1 |
| Phase 2 | 3 | Completed 2, Withdrawn 1 |
Follow Eye Infections, Bacterial: new trials by email Literature Review of Eye Infections, Bacterial trials Research Report on Eye Infections, Bacterial
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis Fusidic Acid 1%, Placebo - Bacterial Conjunctivitis | Phase 3 | Recruiting | Baxis Pharmaceuticals, Inc. | 400 | 2025-03-21 | 2026-03-17 |
| Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs ) Albendazole on Day 1, Ivermectin on Day 1, Diethylcarbamazine on day 1 - Trachoma, Yaws | Phase 3 | Completed | Lihir Medical Centre | 20000 | 2018-10-01 | 2019-02-28 |
| Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%. Pazufloxacin, Zymar - Conjunctivitis, Bacterial | Phase 3 | Terminated | Laboratorios Sophia S.A de C.V. | 46 | 2018-10-01 | 2021-08-24 |
| Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo SHP640, PVP-I 0.6%, Placebo - Bacterial Conjunctivitis | Phase 3 | Completed | Shire | 753 | 2017-03-29 | 2021-06-09 |
| Sanitation, Water, and Instruction in Face-washing for Trachoma I/II Water, sanitation, and hygiene (WASH) intervention, Standard of care WASH intervention, Azithromycin - Trachoma | Phase 3 | Completed | University of California, San Francisco | 47605 | 2015-12-05 | 2026-06-04 |
| Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis Vancomycin 1.1%, Placebo - Bacterial Conjunctivitis | Phase 3 | Completed | Kurobe LLC | 303 | 2015-05-01 | 2024-10-23 |
| Nepal Elimination of Trachoma Study Azithromycin - Trachoma | Phase 2 / Phase 3 | Withdrawn | University of California, San Francisco | 2014-08-01 | 2015-05-21 | |
| Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis Besifloxacin, Vehicle - Bacterial Conjunctivitis | Phase 3 | Terminated | Bausch & Lomb Incorporated | 136 | 2013-02-01 | 2014-10-01 |
| Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection azithromycin 1.5%/Loteprednol 0,5% + placebo, azithromycin 1.5% + Loteprednol 0,5% (separately) - Ocular Inflammation, Infection Associated Blepharitis | Phase 3 | Withdrawn | Adapt Produtos Oftalmológicos Ltda. | 2012-12-01 | 2014-12-11 | |
| An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients Moxifloxacin ophthalmic solution, 0.5%, Ofloxacin ophthalmic solution, 0.3% - Bacterial Conjunctivitis | Phase 3 | Completed | Alcon Research | 985 | 2012-05-01 | 2015-05-12 |
| Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis Besivance, Gatifloxacin - Bacterial Conjunctivitis | Phase 3 | Terminated | Bausch & Lomb Incorporated | 33 | 2011-05-01 | 2014-09-03 |
| Efficacy Maxinom® And Maxitrol® in Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis MAXINOM®, Maxitrol® - Bacterial Conjunctivitis, Acute | Phase 3 | Unknown | Azidus Brasil | 70 | 2011-02-01 | 2010-10-25 |
| Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle Besivance, Vehicle - Bacterial Conjunctivitis | Phase 3 | Completed | Bausch & Lomb Incorporated | 518 | 2010-06-01 | 2013-05-01 |
| Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis Besifloxacin, Vehicle (Placebo) - Bacterial Conjunctivitis | Phase 2 / Phase 3 | Completed | Bausch & Lomb Incorporated | 474 | 2009-10-01 | 2012-03-29 |
| Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%, Moxifloxacin AF Vehicle - Bacterial Conjunctivitis | Phase 3 | Completed | Alcon Research | 1179 | 2008-10-01 | 2018-01-02 |
| A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis Gatifloxacin 0.5% eye drops, placebo eye drops - Bacterial Conjunctivitis | Phase 3 | Completed | Allergan | 859 | 2008-02-01 | 2019-04-23 |
| Comparison of Combination Antibiotics Eyedrop to Artificial Tear in Hordeolum After Incision and Curettage neomycin sulfate, polymyxin B sulfate and gramicidin, Artificial tear - Hordeolum | Phase 3 | Unknown | Chulalongkorn University | 120 | 2007-09-01 | 2010-11-23 |
| A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis Gatifloxacin 0.5% eye drops, placebo eye drops - Bacterial Conjunctivitis | Phase 3 | Completed | Allergan | 578 | 2007-08-01 | 2011-11-30 |
| AL-15469A for the Treatment of Bacterial Conjunctivitis Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%, Moxifloxacin hydrochloride ophthalmic solution 0.5% as base - Bacterial Conjunctivitis | Phase 3 | Completed | Alcon Research | 695 | 2006-05-01 | 2016-11-18 |
| AL-15469A for the Treatment of Bacterial Conjunctivitis quinolone - Bacterial Conjunctivitis | Phase 3 | Completed | Alcon Research | 600 | 2005-11-01 | 2009-09-29 |
Showing 20 of 26. Sign in to see all of them.
Conjunctivitis, Bacterial (20) · Conjunctivitis (5) · Trachoma (4) · Eye Infections (3) · Bacterial Infections (1) · Blepharitis (1) · Chlamydia Infections (1) · Conjunctival Diseases (1) · Elephantiasis, Filarial (1) · Eye Diseases (1) · Hordeolum (1) · Infections (1) · Keratitis (1) · Neglected Diseases (1)
Bacterial Infections and Mycoses (26) · Bacterial Infections (25) · Eye Diseases (25) · Infections (25) · Conjunctival Diseases (24) · Eye Infections (23) · Conjunctivitis (20) · Chlamydiaceae Infections (5) · Conjunctivitis, Bacterial (5) · Corneal Diseases (5) · Gram-Negative Bacterial Infections (5) · Chlamydia Infections (4) · Eyelid Diseases (2) · Communicable Diseases (1)
Azithromycin (8) · Gatifloxacin (4) · besifloxacin (4) · Moxifloxacin (2) · Ophthalmic Solutions (2) · Albendazole (1) · Alkalies (1) · Diethylcarbamazine (1) · Gramicidin (1) · Health (1) · Hygiene (1) · Ivermectin (1) · Lubricant Eye Drops (1) · Maxitrol (1) · Methods (1)
Alcon Research (4) · Bausch & Lomb Incorporated (4) · Allergan (2) · Laboratoires Thea (2) · Merck Sharp & Dohme LLC (2) · University of California, San Francisco (2) · Adapt Produtos Oftalmológicos Ltda. (1) · Azidus Brasil (1) · Baxis Pharmaceuticals, Inc. (1) · Chulalongkorn University (1) · Kurobe LLC (1) · Laboratorios Sophia S.A de C.V. (1) · Laser Microsurgery Centre, Poland (1) · Lihir Medical Centre (1) · National Eye Institute (NEI) (1)
United States (13) · Brazil (2) · Poland (2) · Australia (1) · Austria (1) · Canada (1) · China (1) · Estonia (1) · Ethiopia (1) · France (1) · Hungary (1) · India (1) · Israel (1) · Italy (1) · Mexico (1)
Johnson Varughese (2) · Bruce D Gaynor, MD (1) · Catherine Allaire, MD (1) · Dionna M Wittberg, MPH (1) · Helen Yu, Lead CSM (1) · Jeremy D Keenan, MD, MPH (1) · Jerzy Szaflik, MD,Ph.D. (1) · Lucy John, MD (1) · Michael R Paterno, OD (1) · Parima Hirunwiwatkul, MD (1) · Rubens Belfort Jr., MD (1)
PMID 21681652, PMID 17652708, PMID 18374301, PMID 21397770, PMID 22420526, PMID 22644963, PMID 25244402, PMID 33619183, PMID 34919861, PMID 38134305, PMID 38991011, PMID 41314021, PMID 41548574
2016 (1), K23EY019881 (1), U10EY023939 (1)